Randomized controlled trials 6: On contamination and estimating the actual treatment effect

Methods in Molecular Biology

Volumn 1281, Issue , 2015, Pages 249-259

  Parfrey, Patrick S ^a  

^a NONE

Author keywords

Accelerated failure time models; Censoring; Drop in; Drop out; Inverse probability of censoring weights; Non adherence; Randomized controlled trials

Indexed keywords

CINACALCET;

ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL DECISION MAKING; DRUG CONTAMINATION; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; TREATMENT REFUSAL; DECISION MAKING; PROBABILITY; PROCEDURES; STATISTICAL MODEL; TREATMENT OUTCOME;

DECISION MAKING; HUMANS; MODELS, STATISTICAL; PROBABILITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84924311170     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2428-8_14     Document Type: Article

References (12)

1. Sussman JB, Hayward RA (2010) Using instrumental variables to adjust for treatment contamination in randomized controlled trials. BMJ 340:c2073. doi: 10.1136/bmj.c2073
2. Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. BMJ 340:c332
3. Gupta SK (2011) Intention-to-treat concept: a review. Perspect Clin Res 2:109–112
4. Robins JM, Finkelstein DM (2000) Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 56:779–788
5. Hernan MA, Brumback B, Robins JM (2000) Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11:561–570
6. Robins JM, Hernan MA, Brumbach B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550–560
7. Morden JP, Lambert PC, Latimer N, Abrams KR, Wailoo AJ (2011) Assessing methods for dealing with treatment switching in randomized controlled trials: a simulation study. BMC Med Res Methodol 11:4
8. Greenland S, Lanes S, Jara M (2008) Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation. Clin Trials 5:5–13
9. Branson M, Whitehead J (2002) Estimating a treatment effect in survival studies in which patients switch treatment. Stat Med 21: 2449–2463
10. Chertow GM, Block GA, Correa-Rotter R et al (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. New Engl J Med 367:2482–2494
11. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P (2007) Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2:898–905
12. Snapinn SM, Jiang Q, Iglewicz B (2004) Informative noncompliance in endpoint trials. Curr Control Trials Cardiovasc Med 5:5